New hope for tough cancers: drug targets genetic weakness
NCT ID NCT02286687
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 32 times
Summary
This study tests a drug called talazoparib in 150 people with advanced cancers that have not responded to standard treatments. The drug works by blocking an enzyme that helps cancer cells repair themselves, which may cause them to die. The study focuses on patients whose tumors have specific changes in BRCA or related genes, but excludes breast and ovarian cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1 GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.